Ahead of US gene therapy explosion, big contract drug manufacturer Catalent makes $1.2 billion bet on Paragon Bioservices
As drug developers aggressively pursue gene therapies and their makers, the manufacturing end of the supply chain is also fortifying itself for the wave of therapies expected to hit the market in the coming years. Less than a month after Thermo Fisher unveiled a $1.7 billion deal to swallow Brammer Bio — a company that does contract viral vector manufacturing for cell and gene therapy developers — Catalent is planning to fork over $1.2 billion for private-equity backed Paragon Bioservices.
Basic subscription required
Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.